Clinical Trials Browser

Interventional × Dehydroepiandrosterone × Breast × Clear all

NCT05562518 2025-07-23

GRACE

Phase 4 Recruiting

Breast Neoplasms

NCT04493333 2024-11-27

Vaginal Dehydroepiandrosterone (DHEA) in Postmenopausal Breast Cancer Survivors on Aromatase Inhibitors

Phase 2 Terminated

8 enrolled 11 charts

Vaginal Atrophy

NCT06611514 2024-11-19

PROPOSE

Phase 3 Not yet recruiting

Breast Neoplasms

NCT04705883 2022-02-22

VIBRA

Phase 4 Completed

Breast Neoplasms

NCT03740945 2020-07-31

Effect of Intravaginal Prasterone on Symptoms of VVA in Women Under Treatment With an Aromatase Inhibitor for Breast Cancer

Phase 3 Withdrawn

Breast Neoplasms, Atrophic Vaginitis

NCT00972023 2019-09-17

DHEA in Treating Women Undergoing Surgery for Stage I, Stage II, or Stage III Breast Cancer

Phase 1 Terminated

1 enrolled 3 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01376349 2019-02-07

Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms

Phase 3 Completed

464 enrolled 8 charts

BreastGynecologicOther

Carcinoma, Ovarian Epithelial, Anxiety Disorders, Breast Neoplasms, Uterine Cervical Neoplasms, Depression, Fallopian Tube Neoplasms, Sexual Dysfunction, Physiological, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

NCT02000375 2016-09-29

ARTT

Phase 2 Terminated

Metastatic Breastcancer

NCT00516542 2012-07-24

Dehydroepiandrosterone (DHEA) and Letrozole in Treating Patients With Metastatic Breast Cancer

Phase 1 Terminated

Breast Neoplasms, Breast Neoplasms, Male